DocGo Inc. filings document the company’s mobile health, medical transportation and virtual care business, along with formal disclosures on operating results, governance, listing compliance and capital allocation. Form 8-K reports include quarterly and annual earnings releases, non-GAAP measures such as adjusted gross margin and adjusted EBITDA contribution margin, share repurchase program disclosures, and Nasdaq minimum bid price compliance matters.
Proxy materials cover director elections, advisory executive compensation votes and capital-structure proposals. Other filings record board and committee changes, special committee formation, shareholder voting matters, material-event disclosures and common-stock structure for the Nasdaq-listed issuer.
DocGo Inc. reported first quarter 2026 revenue of $75.6 million, down from $96.0 million a year earlier due to the wind-down of migrant-related programs. Excluding $35.0 million of prior-year migrant revenue, underlying revenue grew 19.3% to $75.6 million from $61.0 million, driven by virtual care and other mobile health services.
GAAP gross margin was 28.1%, with adjusted gross margin of 31.6%. The company posted a net loss of $16.7 million versus a $11.1 million loss last year, and adjusted EBITDA of negative $10.2 million compared to negative $3.9 million. Cash, cash equivalents, restricted cash and investments totaled about $59.9 million as of March 31, 2026, down from $68.3 million at year-end.
Medical Transportation Services revenue edged up to $51.9 million, while Mobile Health Services revenue declined to $23.6 million but more than doubled excluding migrant work. Management raised full-year 2026 revenue guidance to $300–$315 million and reiterated an adjusted EBITDA outlook of negative $5 to $10 million, citing strong demand for virtual care and home-based services.
DocGo Inc. is asking stockholders at its June 16, 2026 virtual annual meeting to elect two Class II directors, approve an advisory vote on executive pay, and authorize a reverse stock split of common stock at a ratio between 1‑for‑5 and 1‑for‑10 with a proportional reduction of authorized common and preferred shares. The company also seeks charter amendments on waiver of corporate opportunities and officer liability exculpation, and ratification of Urish Popeck & Co., LLC as independent auditor for 2026. The proxy details board and committee structure, director and executive compensation, and a performance‑based equity program using relative total shareholder return.
DocGo Inc. announced that board member Stephen K. Klasko, MD will step down from the Board and his committee roles, effective at the conclusion of the 2026 Annual Meeting of Stockholders expected on June 16, 2026. His departure is not due to any disagreement with the company.
The Board appointed long-serving independent director Michael Burdiek as independent Chair of the Board, effective at the same time. Jim Travers will replace Dr. Klasko on the Audit and Compliance Committee and the Nominating and Corporate Governance Committee. On April 21, 2026, the Board also formed a special committee of three directors, chaired by Mr. Burdiek, to assist management in identifying corporate efficiencies and cost reduction opportunities to help accelerate profitability.
DocGo Inc. is soliciting votes at its 2026 virtual Annual Meeting on June 16, 2026 to elect two Class II directors, approve executive compensation on a non-binding basis, and seek stockholder approval of six alternative reverse stock split ratios (1-for-5 through 1-for-10) plus related charter amendments. The Board also asks shareholders to approve amendments on corporate opportunities and officer exculpation and to ratify Urish Popeck & Co., LLC as auditor. The record date for voting is April 20, 2026.
DocGo Inc. Chief Executive Officer Lee Bienstock reported a tax-withholding disposition of 18,811 shares of Common Stock. The shares were withheld at $0.57 per share to satisfy taxes due on previously granted restricted stock units (RSUs), rather than sold in the open market.
Following this transaction, Bienstock directly holds 2,817,470 shares of DocGo Common Stock. The withheld shares relate to RSUs granted under DocGo’s 2021 Stock Incentive Plan, which deliver one share of Common Stock per RSU when they vest.
DocGo Inc registration shows The Vanguard Group filed an amendment to its Schedule 13G/A relating to Common Stock. The filing states amount beneficially owned: 0 and percent of class: 0%. The filing notes an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries for reporting.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026. The filing indicates Vanguard and related managed accounts have rights to dividends or proceeds where applicable but that no other person holds >5% of the class.
DocGo Inc., a mobile healthcare and medical transportation provider, reported 2025 net revenue of $322.2 million, down 47.7% from $616.6 million in 2024, and a $196.4 million net loss, compared with $13.4 million net income in 2024. Operating results included a $178.0 million operating loss, $58.2 million of goodwill impairment and $30.6 million of intangible-asset impairment.
DocGo completed three acquisitions for an aggregate purchase price of $21.1 million in 2025. Government contract work represented approximately 48% of 2025 revenue, compared with 72% in 2024; DocGo attributed the decline to the wind-down of migrant-related programs. As of December 31, 2025, it was not in compliance with its minimum-liquidity financial covenant and said discussions with lenders were active. Nasdaq notified DocGo of a $1.00 minimum-bid-price deficiency; to regain compliance by July 27, 2026, the closing bid must meet or exceed $1.00 per share for at least ten consecutive business days before that date.
DocGo states that current liquidity could raise substantial doubt about its ability to continue as a going concern.
DocGo Inc. reported fourth quarter and full-year 2025 results, raised its 2026 outlook, and began exploring strategic alternatives to maximize shareholder value. Full-year 2025 revenue was $322.2 million, down from $616.6 million in 2024 entirely due to the wind-down of migrant-related programs, which fell from $373.5 million to $69.6 million. Excluding these programs, core businesses grew, including Medical Transportation revenue rising to $200.8 million and Mobile Health Services reaching $121.4 million. The company swung to a 2025 net loss of $196.4 million, including non-cash impairments of $30.6 million in intangible assets, $58.2 million in goodwill, and $5 million on an equity investment. Adjusted EBITDA shifted from a $60.3 million profit in 2024 to a $28.6 million loss in 2025. In the fourth quarter, revenue was $74.9 million and adjusted gross margin was 32.5%. Cash and cash equivalents, including restricted cash and investments, totaled about $68.3 million as of December 31, 2025. For 2026, DocGo now expects revenue of $290–$310 million with an adjusted EBITDA loss of $5–$10 million, improved from prior guidance, and management believes profitability is achievable in the second half of 2026.
DocGo Inc. investor Stanley Vashovsky filed Amendment No. 2 to his Schedule 13D, showing a sharp reduction in his ownership. He now beneficially owns 241,348 shares of common stock, or 0.2% of the class, based on 97,813,372 shares outstanding as of November 7, 2025.
Vashovsky originally received over 13.1 million shares through the Ambulnz merger and additional equity awards for his service as Chief Executive Officer, non-executive Chair, and consultant. Between 2022 and February 24, 2026, he gifted multiple large blocks of stock to estate-planning and charitable trusts, including 4,914,451 shares to a not-for-profit organization, leaving him below the 5% beneficial ownership threshold.